September 18th 2024
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
September 3rd 2024